A Phase 2 interventional study of Dietary Counselling combined with Omega-3 Supplementation in Generalized Anxiety Disorder, sponsored by The Canadian College of Naturopathic Medicine. Completed at 1 site in Canada. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-04-04.
Sponsored by The Canadian College of Naturopathic Medicine · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies in Generalized Anxiety Disorder with a site in Canada — 7 open to participants now, 11 under way, none of them phase 3. Generalized Anxiety Disorder · Canada.
Among the 50 studies in Generalized Anxiety Disorder with a site in Canada, this one is the 26th largest by enrollment of the 45 interventional ones that give a count, is one of 5 that started in 2022, is one of 3 in phase 2, and was the 43rd registered.
518 studies on the registry are indexed under Generalized Anxiety Disorder; 125 are open to participants now.
Browse Generalized Anxiety Disorder studies →7 of the 50 studies in Generalized Anxiety Disorder with a site in Canada are open now. Recruiting first, the newest first:
Claudio N Soares · Sites in Canada
Ages 18–60
Fraser Health · Sites in Canada
Ages 19+
Queen's University · Sites in Canada
Ages 18–65
Universite du Quebec en Outaouais · Sites in Canada
Ages 14–18 · Healthy volunteers
Dr. Rafael Freire · Sites in Canada
Ages 18–65
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 88 Generalized Anxiety Disorder studies recruiting now, 32 (36%) set no upper age limit and 54 (61%) stop at 75 or younger; 15 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 50 is below the median of 83 across 440 interventional studies indexed under Generalized Anxiety Disorder.
Median enrollment 63 across the 45 interventional studies, 380 across the 5 observational. Of the 34 that completed or were terminated, 3 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 50 have an industry lead sponsor. The 10 most frequent:
The Canadian College of Naturopathic Medicine is the lead sponsor of 19 studies on the registry; 1 is open to participants now.
The Canadian College of Naturopathic Medicine has 1 study filed under Generalized Anxiety Disorder — fewer than ten, so there is no comparison to draw.
2 of the studies in Generalized Anxiety Disorder with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06856161Fraser HealthA Novel Blood Test as a Biomarker in Mental Health | 2027-03-15 |
| NCT05574140McGill University Health Centre/Research Institute of the McGill University Health CentreBreathinG-induced Myocardial and Cerebral Perfusion in Anxiety Disorders | 2027-05-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 50 studies in Generalized Anxiety Disorder with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will assess the feasibility and acceptability of a combination intervention including dietary counselling and omega-3 fatty acid supplementation among women with generalized anxiety disorder. It will be randomized and wait-list controlled with 25 participants completing the 12-week intervention immediately and the other 25 participants completing the intervention after a 12-week wait period.
Generalized Anxiety Disorder (GAD) is a common mental health disorder involving high levels of worry or tension. The symptoms are persistent and distressing and interfere with an individual's functioning and quality of life. Clinical evidence suggests that nutritional interventions, based on the Mediterranean diet and omega-3 fatty acid supplementation improve the symptoms of depression. To date, the effect of diet change interventions on anxiety symptoms has not been studied in trials involving people with diagnosed anxiety disorders. The primary objective of this study is to test the feasibility and acceptability of a dietary counselling and omega-3 fatty acid supplementation intervention delivered to adult women with GAD. The secondary objectives include measuring changes in anxiety symptom severity, measuring changes in quality of life, measuring changes in biomarkers and evaluation of the components of the program.
This study is a randomized, wait-list controlled pilot trial delivering a 12-week, dietary counselling intervention and omega-3 supplementation to 50 adult women with GAD. Participant will complete seven individual counselling sessions which include nutrition education, personalized recommendations, mindful eating techniques, motivational interviewing, and goal setting. They will be provided with recipes, instructional videos, and food items. Questionnaires and blood work will be completed at baseline, after the wait period (for those in the wait-list group) and after the intervention. The questionnaires will measure changes in anxiety symptom severity, quality of life, diet quality, mindful eating behaviours, and self-efficacy and lab tests will measure changes in biomarkers of nutritional status. All participants will be asked to complete a brief satisfaction survey concerning the participant's level of satisfaction with the program, the aspects which were helpful or unhelpful, and opportunities for improvement. A sub-sample will be recruited to participate in a brief focus group in order to obtain more detailed qualitative responses about the participant experience and participant satisfaction. Additional information will be collected to characterize study participants including demographic information, body mass index, physical activity and food security.
Results from this study will lay the foundation for future large-scale studies in this area and may provide preliminary evidence of the role of diet counselling and omega-3 supplementation in the management of GAD.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dietary Counselling (7 bi-weekly sessions) plus omega-3 supplementation
Combination Product: Dietary Counselling combined with Omega-3 Supplementation
Participants will wait 12 weeks and then complete the same intervention as the Immediate Start arm.
Dietary Counselling: Seven, bi-weekly counselling sessions over 12-weeks conducted by a licensed Naturopathic Doctor. Each session will be 45-60 minutes in length. The recommendations will be based on the Mediterranean diet and the results of a recent scoping review which summarized the research related to diet and anxiety. The intervention will include motivational interviewing, mindful eating techniques, goal setting and action planning. A range of resources related to meal planning, recipes, cooking education, shopping lists and tracking sheets will be provided in an individualized manner. Dietary Supplement: AquaOmega High EPA Omega-3 capsules will be taken at a dose of four capsules, once daily (containing a total of 3456 mg of omega-3 fatty acids: 2659mg of Eicosapentaenoic acid (EPA), 532mg of docosahexaenoic acid (DHA), and 800IU of Vitamin D), with a meal.
Feasibility of Participant Recruitment and Intervention Delivery
Feasibility will be assessed by measuring the time to recruit and enrol 50 participants. Additionally, we will compare the intervention protocol with the intervention activities delivered.
Time frame: 8 months
Acceptability of the Intervention by Study Participants
Acceptability will be assessed by measuring the number of diet counselling sessions completed. Additionally, participants will be asked to complete a brief satisfaction survey concerning the participant's level of satisfaction with the program, the aspects which were helpful or unhelpful, and opportunities for improvement. A sub-sample will be recruited to participate in a brief focus group in order to obtain more detailed qualitative responses about the participant experience and participant satisfaction.
Time frame: 12 weeks
Anxiety Symptom Severity: The Beck Anxiety Inventory
The Beck Anxiety Inventory is a validated 21-item self-report inventory for measuring the severity of anxiety in participants with psychiatric illness. Answers to each item are given a score of 0 (not at all), 1 (mild), 2 (moderate) or 3 (severely), total scores range from 0 to 63 (minimal anxiety levels (0-7), mild anxiety (8-15), moderate anxiety (16-25), and severe anxiety (26-63)). The Beck Anxiety Inventory will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.
Time frame: 12 weeks
Diet Quality: MEDI-LITE Questionnaire
MEDI-LITE is a validated questionnaire that measures daily and weekly consumption of food typical and non-typical to the Mediterranean diet. Typical Mediterranean diet foods are scored 2 for high consumption, 1 more moderate and 0 for low. Non-typical Mediterranean diet foods are scored 2 for low consumption, 1 for moderate and 0 for high. Scores range from 0 (low consumption) to 18 (high consumption). The MEDI-LITE questionnaire will be completed to assess adherence to the Mediterranean diet at baseline, after the wait period (for those in the waitlist group) and after the intervention.
Time frame: 12 weeks
Quality of Life: PROMIS-29 v2.1
The PROMIS-29 is a validated scale using 4 items scored on a 1-5 scale on intensity to assess 7 health domains (physical function, anxiety, depression, fatigue, sleep disturbance, ability to participate in social roles and activities and pain interference). Higher score equals more of the concept being measured (e.g., more Fatigue, more Physical Function). PROMIS-29 will be used to assess quality of life at baseline, after the wait period (for those in the waitlist group) and after the intervention.
Time frame: 12 weeks
Mindful Eating Behaviour: Mindful Eating Questionnaire
The MEQ is a 28-item scale that measures five factors associated with mindful eating (emotional responses, distraction, external cues, awareness and disinhibition). The questionnaire will be used to measure behaviour change and qualitatively assess the acceptability of the intervention. Each item is scored on a 1-4 scale, higher scores signify more mindful eating. The scores are added together and divided by the number of items answered to get a total summary score. The minimum score is 1 and the maximum score is 4. The MEQ will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.
Time frame: 12 weeks
Self Efficacy: General Self-Efficacy Scale
The GSE is a 10-item validated questionnaire that measures an individual's belief in their ability to overcome and respond to difficult scenarios. Answers to each item are given a score of 0 (not at all true), 1 (barely true), 3 (moderately true) or 4 (exactly true), higher scores correlate to greater self-efficacy. The minimum score is 10 and the maximum score is 40. The GSE will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.
Time frame: 12 weeks
OmegaScore
Summed EPA, DHA and DPA as a percentage of total fatty acids in whole blood as a measure of omega-3 status. This blood test will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.
Time frame: 12 weeks
Fasting Cholesterol Panel
Measures of serum cholesterol including LDL, HDL, triglycerides and total cholesterol. This blood test will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.
Time frame: 12 weeks
Hemoglobin A1c
Measure of the average blood sugar in the past 3 months. This blood test will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.
Time frame: 12 weeks
Serum Vitamin C
Measure of serum levels of vitamin C as an objective marker for fruit and vegetable intake. This blood test will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.
Time frame: 12 weeks
Serum Beta-carotene
Measure of serum levels of beta-carotene as an objective marker for fruit and vegetable. This blood test will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.
Time frame: 12 weeks
C-reactive Protein
CRP will be used to measure inflammation levels. This blood test will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.
Time frame: 12 weeks
HOMA-IR
Homeostatic Model Assessment of Insulin Resistance, calculated using fasting insulin and fasting glucose. Formula: fasting glucose (mg/dL) X fasting insulin (mU/L) / 405. A higher value suggests more insulin resistance. These blood tests and calculation will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.
Time frame: 12 weeks
| Milestone | Immediate Start | Waitlist Control |
|---|---|---|
| Started | 25 | 25 |
| Completed | 23 | 23 |
| Not completed | 2 | 2 |
Feasibility will be assessed by measuring the time to recruit and enrol 50 participants. Additionally, we will compare the intervention protocol with the intervention activities delivered.
| months | Immediate Start | Waitlist Control |
|---|---|---|
| Feasibility of Participant Recruitment and Intervention Delivery | 8 | 8 |
Acceptability will be assessed by measuring the number of diet counselling sessions completed. Additionally, participants will be asked to complete a brief satisfaction survey concerning the participant's level of satisfaction with the program, the aspects which were helpful or unhelpful, and opportunities for improvement. A sub-sample will be recruited to participate in a brief focus group in order to obtain more detailed qualitative responses about the participant experience and participant satisfaction.
| number of sessions attended | Immediate Start | Waitlist Control |
|---|---|---|
| Acceptability of the Intervention by Study Participants | 6.4 ± 1.5 | 6.4 ± 1.9 |
The Beck Anxiety Inventory is a validated 21-item self-report inventory for measuring the severity of anxiety in participants with psychiatric illness. Answers to each item are given a score of 0 (not at all), 1 (mild), 2 (moderate) or 3 (severely), total scores range from 0 to 63 (minimal anxiety levels (0-7), mild anxiety (8-15), moderate anxiety (16-25), and severe anxiety (26-63)). The Beck Anxiety Inventory will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.
| units on a scale | Immediate Start | Waitlist Control |
|---|---|---|
| Baseline | 26.2 (22.94 to 29.48) | 29.3 (24.73 to 33.91) |
| 12 weeks | 11.0 (8.05 to 13.87) | 26.8 (22.09 to 31.56) |
MEDI-LITE is a validated questionnaire that measures daily and weekly consumption of food typical and non-typical to the Mediterranean diet. Typical Mediterranean diet foods are scored 2 for high consumption, 1 more moderate and 0 for low. Non-typical Mediterranean diet foods are scored 2 for low consumption, 1 for moderate and 0 for high. Scores range from 0 (low consumption) to 18 (high consumption). The MEDI-LITE questionnaire will be completed to assess adherence to the Mediterranean diet at baseline, after the wait period (for those in the waitlist group) and after the intervention.
| score on a scale | Immediate Start | Waitlist Control |
|---|---|---|
| Baseline | 7.2 (6.32 to 8.10) | 7.1 (6.33 to 7.91) |
| 12 Weeks | 10.5 (9.55 to 11.49) | 6.9 (6.17 to 7.74) |
The PROMIS-29 is a validated scale using 4 items scored on a 1-5 scale on intensity to assess 7 health domains (physical function, anxiety, depression, fatigue, sleep disturbance, ability to participate in social roles and activities and pain interference). Higher score equals more of the concept being measured (e.g., more Fatigue, more Physical Function). PROMIS-29 will be used to assess quality of life at baseline, after the wait period (for those in the waitlist group) and after the intervention.
| score on a scale | Immediate Start | Waitlist Control |
|---|---|---|
| physical, baseline | 4.54 (4.29 to 4.79) | 4.28 (3.93 to 4.63) |
| physical, 12 weeks | 4.79 (4.61 to 4.97) | 4.20 (3.82 to 4.56) |
| anxiety, baseline | 3.42 (3.18 to 3.65) | 3.55 (3.29 to 3.81) |
| anxiety, 12 weeks | 2.16 (1.81 to 2.52) | 3.25 (2.92 to 3.58) |
| depression, baseline | 2.59 (2.11 to 3.07) | 2.48 (2.03 to 2.95) |
| depression, 12 weeks | 1.72 (1.37 to 2.08) | 2.27 (1.83 to 2.72) |
| fatigue, baseline | 3.78 (3.45 to 4.12) | 3.69 (3.35 to 4.03) |
| fatigue, 12 weeks | 2.75 (2.32 to 3.18) | 3.53 (3.09 to 9.97) |
| social, baseline | 2.83 (2.38 to 3.28) | 2.81 (2.45 to 3.17) |
| social, 12 weeks | 3.79 (3.31 to 4.28) | 3.14 (2.66 to 3.62) |
| pain, baseline | 2.09 (1.59 to 2.59) | 2.24 (1.73 to 2.75) |
| pain, 12 weeks | 1.57 (1.19 to 1.96) | 2.14 (1.62 to 2.66) |
The MEQ is a 28-item scale that measures five factors associated with mindful eating (emotional responses, distraction, external cues, awareness and disinhibition). The questionnaire will be used to measure behaviour change and qualitatively assess the acceptability of the intervention. Each item is scored on a 1-4 scale, higher scores signify more mindful eating. The scores are added together and divided by the number of items answered to get a total summary score. The minimum score is 1 and the maximum score is 4. The MEQ will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.
| units on a scale | Immediate Start | Waitlist Control |
|---|---|---|
| MEQ, baseline | 2.5 (2.38 to 2.73) | 2.6 (2.46 to 2.77) |
| MEQ, 12 weeks | 2.88 (2.73 to 3.03) | 2.5 (2.37 to 2.69) |
The GSE is a 10-item validated questionnaire that measures an individual's belief in their ability to overcome and respond to difficult scenarios. Answers to each item are given a score of 0 (not at all true), 1 (barely true), 3 (moderately true) or 4 (exactly true), higher scores correlate to greater self-efficacy. The minimum score is 10 and the maximum score is 40. The GSE will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.
| units on a scale | Immediate Start | Waitlist Control |
|---|---|---|
| GSE, baseline | 28.9 (27.24 to 30.59) | 28.2 (26.20 to 30.20) |
| GSE, 12 weeks | 32.3 (30.70 to 33.91) | 28.2 (26.49 to 29.95) |
Summed EPA, DHA and DPA as a percentage of total fatty acids in whole blood as a measure of omega-3 status. This blood test will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.
| percentage | Immediate Start | Waitlist Control |
|---|---|---|
| baseline | 3.58 ± 0.74 | 3.43 ± 0.50 |
| week 12 | 7.18 ± 2.12 | 3.47 ± 0.92 |
Measures of serum cholesterol including LDL, HDL, triglycerides and total cholesterol. This blood test will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.
| mmol/L | Immediate Start | Waitlist Control |
|---|---|---|
| triglycerides, baseline | 1.13 (0.93 to 1.32) | 1.02 (0.89 to 1.15) |
| triglycerides, week 12 | 0.88 (0.69 to 1.06) | 0.88 (0.74 to 1.03) |
| Total cholesterol, baseline | 4.72 (4.24 to 5.19) | 4.80 (4.30 to 5.30) |
| Total cholesterol, week 12 | 4.62 (4.11 to 5.13) | 4.75 (4.32 to 5.18) |
| LDL, baseline | 2.63 (2.20 to 3.05) | 2.84 (2.42 to 3.74) |
| LDL, week 12 | 2.67 (2.21 to 3.57) | 2.86 (2.50 to 3.21) |
| HDL, baseline | 1.58 (1.40 to 1.75) | 1.50 (1.34 to 1.66) |
| HDL, week 12 | 1.55 (1.37 to 1.73) | 1.49 (1.32 to 1.67) |
Measure of the average blood sugar in the past 3 months. This blood test will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.
| percentage | Immediate Start | Waitlist Control |
|---|---|---|
| baseline | 5.35 (5.23 to 5.46) | 5.52 (5.15 to 5.88) |
| 12 weeks | 5.36 (5.24 to 5.48) | 5.57 (5.16 to 5.97) |
Measure of serum levels of vitamin C as an objective marker for fruit and vegetable intake. This blood test will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.
| umol/L | Immediate Start | Waitlist Control |
|---|---|---|
| baseline | 49.00 (41.55 to 56.45) | 41.36 (33.99 to 48.74) |
| week 12 | 50.90 (43.17 to 58.64) | 42.25 (35.24 to 49.26) |
Measure of serum levels of beta-carotene as an objective marker for fruit and vegetable. This blood test will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.
| umol/L | Immediate Start | Waitlist Control |
|---|---|---|
| baseline | 0.53 (0.38 to 0.67) | 0.40 (0.29 to 0.52) |
| week 12 | 0.66 (0.49 to 0.83) | 0.44 (0.32 to 0.57) |
CRP will be used to measure inflammation levels. This blood test will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.
| mg/L | Immediate Start | Waitlist Control |
|---|---|---|
| baseline | 3.11 (1.97 to 4.26) | 6.60 (2.77 to 10.43) |
| week 12 | 4.06 (2.27 to 5.85) | 7.49 (2.78 to 12.19) |
Homeostatic Model Assessment of Insulin Resistance, calculated using fasting insulin and fasting glucose. Formula: fasting glucose (mg/dL) X fasting insulin (mU/L) / 405. A higher value suggests more insulin resistance. These blood tests and calculation will be completed at baseline, after the wait period (for those in the waitlist group) and after the intervention.
| HOMA-IR index | Immediate Start | Waitlist Control |
|---|---|---|
| baseline | 2.94 (2.01 to 3.87) | 4.05 (1.86 to 6.25) |
| 12 weeks | 2.92 (1.89 to 3.95) | 4.81 (0.93 to 8.69) |
Collected over 12 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Immediate Start | 0/25 (0%) | 0/25 (0%) | 21/25 (84%) |
| Waitlist Control | 0/25 (0%) | 0/25 (0%) | 0/25 (0%) |
| Event | Immediate Start | Waitlist Control |
|---|---|---|
| GI symptomsGastrointestinal disorders | 19/25 | 0/25 |
| heart palpitationsCardiac disorders | 2/25 | 0/25 |
| pruritisSkin and subcutaneous tissue disorders | 1/25 | 0/25 |
| Age, Continuous(years) | Immediate Start | Waitlist | Total |
|---|---|---|---|
| Mean | 39 ± 14 | 35 ± 10 | 37 ± 12 |
| Sex: Female, Male(Participants) | Immediate Start | Waitlist | Total |
|---|---|---|---|
| Female | 24 | 25 | 49 |
| Male | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Immediate Start | Waitlist | Total |
|---|---|---|---|
| Black | 2 | 4 | 6 |
| East/Southeast Asian | 3 | 0 | 3 |
| First Nations/Indigenous/Metis | 1 | 0 | 1 |
| Latino | 2 | 1 | 3 |
| Middle Eastern | 1 | 0 | 1 |
| South Asian | 1 | 3 | 4 |
| White | 13 | 14 | 27 |
| Another race | 1 | 2 | 3 |
| Do not know | 0 | 1 | 1 |
| Baseline Beck Anxiety Inventory Score(units on a scale) | Immediate Start | Waitlist | Total |
|---|---|---|---|
| Mean | 26.2 ± 8.17 | 29.3 ± 11.71 | 27.8 ± 10.1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2022 to primary completion in Nov 2023, 15 months.
Results were first posted in Apr 2025, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Generalized Anxiety Disorder →
The Canadian College of Naturopathic Medicine